Data demonstrate ATH434 slows disease progression and stabilizes orthostatic hypotension –– New analysis increases overall confidence in the ...

The MS for Dwyfor Meirionnydd hosts an event at the Senedd, urging greater support for rare diseases, especially in the Welsh ...

The Mid-Ohio Valley Parkinson’s Support Group’s Parkinson’s and Movement Disorder Symposium is an educational event for those ...

Alterity Therapeutics (ASX:ATH) CEO Dr David Stamler presented new analyses from the phase II double-blinded ATH434-201 trial in MSA, showing positive effects on slowing disease progression and ...

Detailed price information for Alterity Therapeutics Ltd ADR (ATHE-Q) from The Globe and Mail including charting and trades.

Alterity Therapeutics (ATHE) announced that data from the ATH434-201 randomized, double-blind Phase 2 clinical trial in Multiple System Atrophy ...

Could an anomaly in the developing brain explain motor difficulties occurring decades later in people with rare movement ...

We are heartbroken at the loss of our beloved Kathleen. She was born in Missoula to Patrick and Teresa Mangan, who emigrated to Montana from Ireland. Kathleen graduated from Loyola Sacred Heart High ...

Drug developers today have released a slew of announcements updating their programs – and the message is slow but steady ...

On October 13, GemVax & KAEL announced that it held a plaque unveiling ceremony for the "International Progressive ...